A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients

Post-marketing Clinical Study of Ramosetron Hydrochloride (Irribow Tablets) - Double-blind, Parallel-group Comparative Study in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome

A study to verify the superiority of ramosetron hydrochloride (Irribow Tablets) to placebo for male patients with diarrhea-predominant irritable bowel syndrome (D-IBS) and to evaluate its safety.

Inclusion Criteria:

• Patients meeting the Rome III Diagnostic Criteria
• Loose (mushy) or watery stools within the last 3 months

Exclusion Criteria:

• Patients with a history of surgical resection of the stomach, small intestine or large intestine
• Patients with a history or current diagnosis of inflammatory bowel disease (Crohn's disease or colitis ulcerative)
• Patients with a history or current diagnosis of colitis ischemic
• Patients with a current diagnosis of enteritis infectious
• Patients with a current diagnosis of hyperthyroidism or hypothyroidism
• Patients who are currently participating in another clinical trial (including a post-marketing clinical study) or those who participated in another clinical trial (including a post-marketing clinical study) within 12 weeks before the study
• Patients with a history or current diagnosis of malignant tumor
• Patients with a history of abuse of drugs or alcohol within 1 year or those who are currently abusing them